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The present study deals with the preparation of polyurethane (PU) films impregnated with a nonsteroidal anti-inflammatory drug,
tolfenamic acid (TA). Solvent evaporation technique has been employed for the preparation of TA-PU films in two different ratios
of 1 : 2 and 1 : 5 in Tetrahydrofuran (THF) or THF-ethanol mixtures.The prepared films were characterized using X-Ray Diffraction
(XRD), Differential ScanningCalorimetry (DSC), Fourier Transform Infrared Spectroscopy (FTIR), Scanning ElectronMicroscopy
(SEM), and release studies. The results indicate transformation of crystalline TA to its amorphous form.The degree of crystallinity
changes both by increasing the polymer concentration and solvent used for the film preparations. The release profiles of TA were
also found to be affected, showing a decrease from approximately 50% to 25% from 1 : 2 to 1 : 5 ratios, respectively.
1. Introduction
Polymer films are generally used for therapeutic purposes
and a number of workers have reported the use of different
polymeric films for the delivery of various therapeutic agents
via different routes [1–6]. Among the variety of polymers
available, polyurethanes (PU) are a family of polymers that
are widely used as biomaterials in clinical applications.
Their use not only in the medical field but also in other
commercial applications is significant in many areas, since
their easy structure manipulation allows the control of their
chemical, physical, andmechanical characteristics [7–10]. PU
are used in a wide range of biomedical applications due
to their excellent physical and mechanical properties and
relatively good blood compatibility [8–12]. They also possess
great diversity due to their different chemical compositions
and properties such as elasticity, tolerance in the body,
durability, and compliance, which are generally superior to
other biomaterial polymers [9, 12–14]. Recently, it has been
reported that PU films prepared through solvent evaporation
technique were effective in the controlled in vitro delivery of
curcumin against human lung cancer cells [4].
Polyurethanes are among the many commercially impor-
tant classes of polymers. The term “polyurethane” is more
one of convenience than of accuracy, since these poly-
mers are not derived by polymerising a monomeric ure-
thane and are derived from the reaction of cyano (–NCO)
and hydroxyl (–OH) groups to form urethane linkage.
PU is a class of polymers, which contains a signifi-
cant number of urethane groups contained within the
molecule, although not necessarily repeating in a regular
order [11]. A urethane group is formed by the chem-
ical reaction between a hydroxyl and isocyanate group
(Figure 1(a)).
PU contains intermolecular urethane linkages that are
formed due to the condensation reaction of polyisocyanates
and polyols, and most commonly diisocyanates and diols
are used to obtain linear PU. Typically PU possesses three
monomers: a diisocyanate, a macroglycol (diol), and a chain
extender [7, 10, 13]. Polymeric materials may be dissolved
either in pure solvents or in mixtures of different solvents.
Mixtures are used in order to enhance the solvency power
of the primary solvents. Tetrahydrofuran (THF) is found to
be one of the best solvents for PU with a polymer interaction
parameter value of 0.78 [15].
Tolfenamic acid (2-[(3-chloro-2-methylphenyl)amino]-
benzoic acid) (Figure 1(b)) is a nonsteroidal anti-inflamma-
tory drug (NSAID) and is used in the treatment of migraine,
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Figure 1: Structures of (a) PU and (b) TA.
dysmenorrhoea, rheumatoid arthritis, or osteoarthritis, and
so forth [16, 17]. Recently, it has been discovered that this
drug can slow down the progression of Alzheimer disease [18,
19]. In addition, it also possesses novel anticancer properties
and a number of workers have employed tolfenamic acid
(TA) successfully against variety of cancers [20–24]. TA
occurs in crystalline form and is insoluble in water [17]. It
has a bioavailability of only 60%–75% [25, 26]. One of the
most common ways of increasing a drugs’ solubility and
bioavailability is converting it to an amorphous form.
A number of methods have been reported to make drugs
amorphous and hence more soluble and bioavailable [27–
33]. But often it has been observed that the metastable
amorphous forms have the tendency of recrystallization
during storage, which is the major drawback in their prepa-
ration. One of the widely used approaches for making the
crystalline drug amorphous and avoid recrystallization is
to complex it with a suitable polymer in optimum concen-
tration. Polymers having the tendency to form hydrogen
bonds with drugs are usually used for this purpose. Further-
more, the technique employed for complexation also affects
the solid state properties of the crystalline drug particles
[27–37].
The aim of this study has to evaluate the changes in the
physical state properties of TA after its complexation with PU
through solvent evaporation technique. As mentioned above
both PUandTAhave gained significantmedical and pharma-
ceutical importance in the recent past. In view of their invalu-
able potential this is the first timewhen such combination has
been reported. It is envisaged that the impregnation of TA in
the polymeric matrix and the study of its release pattern may
help in the development of novel therapeutic films for clinical
applications.
2. Experimental
2.1. Materials. TA (99.97%) was purchased from Sigma-
Aldrich Company Ltd. (Dorset, UK), PU resins (Z3A1,
polyether-urethane) fromBiomer Technology Ltd. (Runcorn,
UK), THF (99.99%) and ethanol (99.99%) from Fisher
Scientific Inc. (Loughborough, UK). All other chemicals and
solvents used in this study were of analytical grade and
purchased from Sigma-Aldrich Company Ltd. (Dorset, UK).
2.2. Preparation and Storage of Drug-Polymer Films. TA-PU
films in 1 : 2 and 1 : 5 ratios were prepared through solvent
evaporation technique by two different methods.
2.2.1. Method I. In the first method, TA (1% w/v) and PU
solutions (2% and 5% w/v) were prepared in THF. The drug
solutionwas added in equal volumes in the polymer solutions
in order to obtain the desired ratios, that is, 1 : 2 and 1 : 5.
A measured volume was spread over the glass slide (76 ×
26mm) by the help of a glass pipette and kept for drying at
room temperature in a fume cupboard (AFA 1000, Clean Air
Limited, Bolton, UK) with an air flow rate of 1.50m/sec.
2.2.2.Method II. In the secondmethod, TA solution (1%w/v)
was prepared in ethanol and PU solution (2% and 5% w/v) in
THF. Both solutions were mixed together in equal volumes
in similar pattern to method I and poured over a glass slide
using a glass pipette and dried as described above.
Pure polymer films (2% and 5%) were also prepared
in the similar manner that served as control. The polymer
solutions withmore PU concentration, that is, 5%were found
to be more viscous as compared to PU solutions of 2%. All
the prepared films were protected from light throughout the
experiments and stored in a desiccator containing silica gel at
room temperature for up to 3 months.
2.3. Characterization Studies. As described above, the aims
and objectives of this study have been to study the drug-
polymer interaction and any changes in the solid state prop-
erties of TA. Therefore, the prepared films were thoroughly
characterized by employing different analytical techniques to
study these physical and chemical interactions.
2.4. X-Ray Diffraction (XRD) Analysis. The XRD patterns
for the films were obtained with STOE STADI-P high-
resolution diffractometer (Darmstadt, Germany) usingCuK-
alpha1 radiation (wavelength = 1.54051 A˚). Data was collected
over the 2𝜃 range of 5–60∘ for 60min by using proprietary
STOEWinXPOW software.
2.5. Differential Scanning Calorimetry (DSC). The sam-
ples were studied for their thermal behaviour by DSC 6
(PerkinElmer, USA) using pin-hole aluminium pans with
lids. The samples were weighed accurately (3 ± 0.1mg) and
heated from 30 to 250∘C at a rate of 10∘C per min. Nitrogen
with a flow rate of 20mL/min was used as a purge gas and
indium and zinc standards were used for the calibration
of the instrument. Pyris 7.0 software was used for data
analysis.
2.6. Fourier Transform Infrared (FTIR) Spectroscopy. FTIR
studies were performed using a Nicolet Nexus FTIR spec-
trophotometer (Thermo Fisher Scientific Inc., USA). The
thin films were analysed in transmissionmode, accumulating
BioMed Research International 3
64 scans at 4 cm−1 resolution in the spectral range of 4000–
400 cm−1. The spectral data was analysed using the OMNIC
7.4 software.
2.7. Scanning Electron Microscopy (SEM). SEM studies were
performed by using Inspect F microscope (FEI, Holland)
with an accelerating voltage of 5 KV. The samples were
mounted on a 0.5 inch aluminium stubwith the help of 12mm
double-sided adhesive carbon tabs (Agar Scientific, UK).The
mounted samples were then outlined with silver solution
and subjected to carbon coating using Speedivac carbon
coating unit (Model 12E6/1598) to make them electrically
conductive.Themagnification of themicroscopewas selected
as required for the detailed study ofmorphological changes of
the samples.
2.8. Release Studies. The release studies of the TA-PU films
were performed on a USP type II paddle dissolution appara-
tus (Model VDA-1D, Veego Instruments Corporation, India).
Phosphate buffer (0.2M, pH 7.2, 500mL) was used as dissolu-
tion medium while temperature and stirring conditions were
maintained at 37 ± 0.5∘C and 50 rpm, respectively. All films
were prepared in a manner to contain same amount of TA
(i.e., 25mg). Each time 5mL of the sample was withdrawn
from the vessel at suitable time intervals and an equal volume
of the dissolution medium was added in order to maintain
the sink condition.The concentration of TA in the withdrawn
samples was determined by the UV spectrophotometric
method according to the method described by Thybo et al.
[31] using an appropriate blank of phosphate buffer with
polymer.
3. Results and Discussion
3.1. Appearance of TA-PU Films. Equal volumes of the solu-
tions were used in the preparation of all films. However,
TA-PU films prepared by two different methods showed
some differences in their appearance. The films prepared by
method I (both drug and polymer in THF) were found to
be more transparent with smooth surface whereas the films
prepared bymethod II (drug in ethanol and polymer in THF)
appeared opaque with slightly rough surface. No signs of
recrystallization or changes in appearance took place in all
the films during storage for up to 3 months in a desiccator.
3.2. Characterization Studies
3.2.1. XRD Studies. In order to confirm the changes in the
physical properties of the crystalline TA, the films were
studied using XRD technique. XRD is usually considered
as the most definite method of detecting and quantifying
the crystalline/amorphous nature of the sample. XRD shows
strong characteristic diffraction peaks for crystalline solids
whereas diffused and hallow diffraction patterns for amor-
phous powders [30].
The pure crystalline TA shows characteristic diffraction
peaks at 2𝜃 values of 5.21∘, 11.58∘, 15.72∘, 18.70∘, 19.77∘, 24.90∘,
25.32∘, 25.90∘, and 26.81∘, respectively (Figure 2(a)). In case
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Figure 2: XRD patterns of (a) TA, (b) PU, TA-PU films prepared by
method I in ratios (c) 1 : 2, (d) 1 : 5, TA-PU films prepared bymethod
II in ratios (e) 1 : 2, (f) 1 : 5.
of PU, a hallow diffraction pattern with no sharp peaks has
been observed in the pure as well as in the control films thus
indicating its amorphous nature. A typical diffraction pattern
has been presented in Figure 2(b). The diffraction patterns
of the 1 : 2 TA-PU films prepared by method I indicated a
marked decrease in the peaks intensity of the crystalline TA
and show very small peaks at around 15.72–18.70∘ and 24.90–
26.81∘ whereas the remaining peaks of the drug have not been
detected (Figure 2(c)). The diffraction pattern of 1 : 5 TA-PU
films also shows similar type of result with comparatively less
intense peaks in the same region (Figure 2(d)). This decrease
in peak intensity clearly indicates that majority of drug has
been transformed to the amorphous form.
The films prepared using ethanol for drug solubilisation
(method II) showed similar type of diffraction patterns for
1 : 2 and 1 : 5 ratios, respectively, but the intensity of the peaks
is comparatively higher to the films prepared in THF only
(method I) (Figures 2(e) and 2(f)).Therefore, method I could
be considered as more effective comparatively in converting
crystalline TA to its amorphous form. Similarly, the difference
in the diffraction pattern of the films indicates that the solvent
also plays an important role in modifying the solid state
properties of the drug in addition to the technique used and
the nature of the polymer. THF evaporates more rapidly as
compared to ethanol-THFmixture [38] and therefore the use
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of THF alone has resulted in greater amorphicity of the drug.
The samples were further subjected to analysis by DSC, FTIR,
and SEM techniques in order to confirm the results obtained
by XRD.
3.2.2. DSC Studies. TheDSC thermogram of pure TA and PU
is given in Figure 3. The melting peak of pure TA has been
observed at around 214∘Cwhereas no peak has been detected
in pure PU in the studied region of 30–250∘C.
In the case of drug-polymer mixtures, no peak has been
observed for any film in the region 30–250∘C (Figure 3),
which is not in agreement with the results of XRD. Increasing
the sample amount up to 10mg or cutting the films in very
small fragments also found in vain. The possible reason for
the absence ofmelting peak could be due to the impregnation
or encapsulation of the drug within the viscous polymer
matrix and PU with its high melting point has restricted the
contact of the melting drug with the base of the aluminium
pan thus leaving no signs of its melting to the detector. On
the basis of these results, it has been concluded that DSC is
not a useful technique in the current study in detecting the
thermal behaviour of crystalline/amorphous form of TA in
the polymer films.
3.2.3. FTIR Spectroscopy. Spectroscopic methods due to their
nondestructive nature can be used along with other solid-
state techniques for quantitative analysis of pharmaceuti-
cal solids. FTIR spectroscopy is considered as a valuable
technique to study the degree of crystallinity based on the
measurement of characteristic peak intensity for its particular
polymorphic crystal state [30]. Infrared technique is also very
useful to study the hydrogen bond formation of polymers
with different drugs [29, 31, 33].Therefore, FTIR spectroscopy
was used in this study to identify the possible interaction and
complexation between TA and PU. It is envisaged that PU
contain –COOHand–NHgroups in its backbone, whichmay
be involved in H-bonding with TA (Figure 1). As described
above, PU is the polymer obtained from the polymerization
of diisocyanate and polyol that contains electron donating
sites; that is, C=O and –NH groups (Figure 1) both of which
are sensitive to the formation of hydrogen bonds with the
drug during complex formation [14, 39].
Peaks at 1661, 1590, 1575, 1500, 1270, and 749 cm−1 are the
most intense, characteristic peaks of TA (Figure 4(a)). The
FTIR spectrum of pure TA shows NH-stretching vibrations
at around 3342–3340 cm−1. However, one of its other poly-
morphic forms gives similar stretching vibrations at 3324–
3315 cm−1. Due to this reason, the spectral region between
3350 and 3300 cm−1 has been monitored for observing the
spectral changes in the crystalline form of TA [31, 33, 40–42].
Similarly, PU is also known to exhibit its characteristic major
NH peak at 3325 cm−1 (Figure 4(b)). Since pure TA and PU
share the same spectral region to exhibit their characteristic
peaks of NH-stretching vibrations, it was difficult to identify
the changes taking place in the peak height of TA in the drug-
polymer films at the spectral region of 3350–3300 cm−1. How-
ever, the films still show broadening of the peak in the same
region that increases with increasing polymer concentration
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Figure 3: DSC thermogram of pure TA, PU, and their mixture. All
TA-PU films showed similar type of pattern.
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Figure 4: FTIR spectra of (a) TA, (b) PU, TA-PU films prepared
by method I in ratios (c) 1 : 2, (d) 1 : 5, TA-PU films prepared by
method II in ratios (e) 1 : 2, (f) 1 : 5. The dotted lines and arrows are
highlighting the regions that show complexation and intermolecular
hydrogen bonding between TA and PU films.
that is a clear indication of complexation between the drug
and the polymer resulting in increased amorphicity of TA
(Figures 4(c)–4(f)).
The other specific peaks for pure TA in the FTIR spectra
could be observed at 1661 cm−1 for the stretching vibrations
of C=O of carboxylic moiety, at 1600–1560 cm−1 for C–
N stretching bands and at ∼1500 cm−1 for NH-bending
vibrations (Figure 4(a)). In the case of 1 : 2 (Figure 4(c)) and
1 : 5 (Figure 4(d)) TA-PU films, prepared by method I, a
marked change has been noted in the peak intensity of
the drug at 1661 cm−1, which is decreased with increasing
polymer concentration suggesting that 1 : 5 TA-PU is more
effective in converting the crystalline nature of the drug to
its amorphous form. The C–N stretching bands have also
been found to decrease in size with increasing polymer
concentration particularly at ∼1575 cm−1 in both 1 : 2 and
1 : 5 TA-PU films (Figures 4(c) and 4(d)). The NH-bending
vibrations at around 1500 cm−1 of the drug could not be
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Figure 5: SEM images of (a) pure TA, (b) 2% PU, (c) 5% PU, TA-PU films prepared by method I in ratios (d) 1 : 2, (e) 1 : 5, TA-PU films
prepared by method II in ratios (f) 1 : 2, (g) 1 : 5.
clearly observed in any of the TA-PU films due to the fact
that the same bending vibrations are exhibited by PU in this
region. However, still the appearance of small shoulder in
the same peak in 1 : 2 ratios (Figures 4(c) and 4(e)) can be
observed which eventually disappeared in 1 : 5 ratios (Figures
4(d) and 4(f)). The sharp peak at 749 cm−1 (Figure 4(a))
corresponds to the C–N deformation [41, 42] which has
also reduced in the films (Figures 4(c)–4(f)) thus further
confirming modification in the solid state properties of TA
due to strong complexation and intermolecular hydrogen
bonding between TA and PU.
The films prepared using ethanol for drug solubilisation
(method II) have been found to demonstrate the similar
spectral pattern as in case of TA-PU films in THF but with
slightly stronger peak intensity as compared to the pure
polymer suggesting the presence of more crystalline drug
(Figures 4(e) and 4(f)). The FTIR data thus further supports
the results of XRD.
3.2.4. SEM Studies. In order to observe any morphological
changes in the drug-polymer particles, the films were anal-
ysed by SEM.The images of pure TA reveal particles of irreg-
ular size with rough surface (Figure 5(a)).The images of pure
PU film show a honeycomb like structure which becomes
more compact and chain like with increasing polymer con-
centration (Figures 5(b) and 5(c)). In case of films prepared by
method I, the particles of TA on the surface of the film in 1 : 2
ratio can clearly be observed (Figure 5(d)). On the contrary,
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Figure 6: Release profiles of TA from TA-PU films. (a) 1 : 2 (method
II), (b) 1 : 2 (method I), (c) 1 : 5 (method II), and (d) 1 : 5 (method I).
The error bars represent the standard deviation where 𝑛 = 3.
fused drug particles with altered physical appearance could
be seen in film with 1 : 5 TA-PU ratio suggesting a better
complexation between the TA and PU (Figure 5(e)). The
1 : 2 TA-PU film prepared by method II shows a mixture of
irregular, smooth as well as rough surface particles indicating
the partial conversion of crystalline TA into its amorphous
form (Figure 5(f)). Similarly, the film with 1 : 5 TA-PU ratio
also exhibits identical appearance of particles that are fused
together but with slightly smoother surface (Figure 5(g)).
These images further confirm the results of XRD and FTIR
indicating the modification in the crystalline nature of TA.
These images also show difference in surface morphology
of the films when prepared by two different methods. More
drug particles could be clearly observed in films prepared by
method II as compared to method I films.
3.2.5. Release Studies. The comparative release pattern of
TA from the different TA-PU films is presented in Figure 6.
Almost 50% of the drug was released from the 1 : 2 ratio films
in the initial 90 minutes prepared by method II. On the same
time about 40% of the drug was released from the films of
same ratio prepared by method I and about 30% and 25%
from the films of 1 : 5 ratio prepared by methods II and I,
respectively.
Films prepared by either method show that with increas-
ing PU concentration the release of TA has been slowed
down despite the fact that increased polymer concentration
has converted more amount of the crystalline drug into
its amorphous form. This could be due to the formation
of viscous PU solutions, which entrapped or encapsulated
the drug more effectively within its matrix and thus slowed
down its release. On the other hand, the effect of method
of preparation on drug release can also be observed as films
prepared by method II showed better release of TA from
the polymer matrix as compared to the films prepared by
method I. This could be attributed to the presence of more
TA particles on the surface of film that are evident from the
SEM images (Figure 5).
4. Conclusion
Characterization of the films confirms the transformation
of a significant amount of crystalline TA to its amorphous
form, which is related to themethods of preparation and con-
centration of polymer. All the characterization data except
DSC confirmed the drug-polymer interaction and it was
observed that 1 : 5 TA-PU films prepared in THF (method I)
were more efficient in converting the drug to the amorphous
form as compared to the other ratio. The films prepared by
dissolving TA in ethanol (method II) were found to contain
comparatively more crystalline TA particles than the films
prepared in THF only. This shows that the solvent used
for drug solubilisation and its evaporation rate also play an
important role in such type of solid-state transformations.
Although films prepared by method I indicated greater
degree of amorphicity but comparatively better release rates
for tolfenamic acid (∼50%) has been observed in films
prepared by method II mainly due to the increased amount
of drug present on the surface of the film. It has also been
observed that TA release slowed down with increasing PU
concentration due to the strong entrapment or encapsulation
of the drug within the polymer matrix.
The present work thus provides useful guidelines to the
researchers and formulators in developing such type of films
that could be effectively used for therapeutic purposes in
various clinical conditions.
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